Changes in cardiovascular biomarkers in HIV-infected patients switching from ritonavir-boosted protease inhibitors to raltegravir

AIDS. 2012 Nov 28;26(18):2315-26. doi: 10.1097/QAD.0b013e328359f29c.

Abstract

Background: : Switching from boosted protease inhibitors (PI/r) to raltegravir (RAL) results in a better plasma lipid profile than continuing PI/r. Whether this strategy affects plasma biomarkers associated with atherosclerosis is unknown.

Methods: : We assessed 48-week changes in fasting lipids and several biomarkers including serum high-sensitivity C-reactive protein (hsCRP), monocyte chemoattractant protein 1 (MCP-1), osteoprotegerin, interleukin (IL) 6, IL-10, tumor necrosis factor alpha (TNF-α), intercellular adhesion molecule 1 (ICAM-1), vascular cell adhesion molecule 1 (VCAM-1), E-selectin and P-selectin, adiponectin, insulin, and D-dimer in otherwise healthy, virologically suppressed HIV-infected patients treated with PI/r who randomly switched from PI/r to RAL or continued with PI/r in the SPIRAL trial. Biomarkers and lipids at baseline and 48-week changes between both study arms were compared. Correlations between changes in biomarkers and changes in lipids were also evaluated.

Results: : Of 273 patients initiating study drugs in the SPIRAL trial, 233 (119 RAL, 114 PI/r) remained on allocated therapy for 48 weeks and had sera available for the purpose of this substudy. Triglycerides (-28%, P < 0.0001), total (-14%, P < 0.0001), low-density lipoprotein (-9%, P = 0.0069), and high-density lipoprotein (-10%, P = 0.0017) cholesterol decreased in RAL relative to the PI/r group. Among biomarkers, hsCRP (-40%, P < 0.0001), MCP-1 (-20%, P = 0.0003), osteoprotegerin (-13%, P = 0.0024), IL-6 (-46%,P < 0.0001), TNF-α (-27%, P = 0.0011), insulin (-26%, P < 0.0001), and D-dimer (-8%, P = 0.0187) decreased in RAL relative to PI/r group, whereas IL-10 (+1%, P = 0.7773), ICAM-1 (-6%, P = 0.1255), VCAM-1(0%, P = 0.8671), E-selectin (-9%, P = 0.2174), P-selectin (-6%, P = 0.3865), and adiponectin (+8%, P = 0.2028) remained unchanged. Biomarkers and lipids changes at 48 weeks were weakly correlated.

Conclusion: : Switching from PI/r to RAL induced significant changes in several cardiovascular biomarkers that were not completely explained by lipid changes.

Publication types

  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Anti-HIV Agents / pharmacology
  • Atherosclerosis / blood*
  • Atherosclerosis / drug therapy*
  • Atherosclerosis / physiopathology
  • Biomarkers / blood*
  • C-Reactive Protein / metabolism
  • Chemokine CCL2 / blood
  • Drug Administration Schedule
  • E-Selectin / metabolism
  • Fasting
  • Female
  • Follow-Up Studies
  • HIV Infections / drug therapy*
  • HIV Infections / metabolism
  • HIV Infections / physiopathology
  • HIV Protease Inhibitors / pharmacology*
  • Humans
  • Interleukin-10 / blood
  • Interleukin-6 / blood
  • Lipids / blood
  • Male
  • Middle Aged
  • Osteoprotegerin / blood
  • P-Selectin / metabolism
  • Pyrrolidinones / pharmacology*
  • Raltegravir Potassium
  • Ritonavir / pharmacology*
  • Tumor Necrosis Factor-alpha / blood
  • Vascular Cell Adhesion Molecule-1 / blood

Substances

  • Anti-HIV Agents
  • Biomarkers
  • CCL2 protein, human
  • Chemokine CCL2
  • E-Selectin
  • HIV Protease Inhibitors
  • Interleukin-6
  • Lipids
  • Osteoprotegerin
  • P-Selectin
  • Pyrrolidinones
  • TNFRSF11B protein, human
  • Tumor Necrosis Factor-alpha
  • Vascular Cell Adhesion Molecule-1
  • Interleukin-10
  • Raltegravir Potassium
  • C-Reactive Protein
  • Ritonavir